Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652573 · ClinicalTrials.gov registry record · NA
Calcitonin for Treating X-linked Hypophosphatemia
A NA study of Hypophosphatemic Rickets, X-Linked Dominant, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01652573 is a NA study of Hypophosphatemic Rickets, X-Linked Dominant that has completed, run by Yale University. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01652573, a NA study of Hypophosphatemic Rickets, X-Linked Dominant, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
X-linked hypophosphatemia (XLH) is the most common form of inherited rickets in the United States. It also causes bone disease in adults. XLH is caused by overproduction of a hormone call FGF23, which makes the body waste phosphate. This study is designed to determine if nasal calcitonin, an already approved drug in the US, can lower blood levels of FGF23 and reduce phosphate wasting in patients with XLH. In this study the investigators will: 1. Determine whether nasal calcitonin significantly lowers integrated 24-hour blood levels of FGF23 in patients with XLH. 2. Evaluate whether nasal calcitonin improves serum phosphate levels in XLH. 3. Assess whether nasal calcitonin improves blood levels of the active form of vitamin D and calcium absorption from the intestine. 4. Make sure that nasal calcitonin is safe and well tolerated.
Conditions Studied
Interventions
- DRUG nasal salmon calcitonin
- DRUG Saline Nasal Spray Placebo
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01652573
The ClinicalTrials.gov registry entry for NCT01652573 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypophosphatemic Rickets, X-Linked Dominant appearing as the primary indexed condition, and to 2 interventions - of which nasal salmon calcitonin is the first listed.
NCT01652573 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01652573 about?
NCT01652573 is a clinical study titled "Calcitonin for Treating X-linked Hypophosphatemia". X-linked hypophosphatemia (XLH) is the most common form of inherited rickets in the United States. It also causes bone disease in adults. XLH is caused by overproduction of a hormone call FGF23, which makes the body waste phosphate. This study is designed to determine if nasal calcitonin, an already...
What is the current status of trial NCT01652573?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2011-03. Estimated completion is 2015-09.
What conditions does trial NCT01652573 study?
This clinical trial studies the following conditions: Hypophosphatemic Rickets, X-Linked Dominant.
What interventions are being tested in trial NCT01652573?
The interventions under investigation include: nasal salmon calcitonin (DRUG), Saline Nasal Spray Placebo (DRUG).
Who is sponsoring clinical trial NCT01652573?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01652573 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatemic Rickets, X-Linked Dominant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.